Technical Analysis for ODT - Odonate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 21.4 -4.08% -0.91
ODT closed down 4.08 percent on Thursday, April 18, 2019, on approximately normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ODT trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -4.08%
New Downtrend Bearish -4.08%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.08%
Wide Range Bar Range Expansion -4.08%
Down 3 Days in a Row Weakness -4.08%
Overbought Stochastic Strength -10.61%

Older signals for ODT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Odonate Therapeutics LLC is a pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer.
Cancer Pharmaceutical Iowa Corcept Therapeutics Urbandale
Is ODT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 2 PLAY, GME and ADXS among after hours movers
Apr 2 Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing
Mar 28 Odonate Therapeutics Initiates CONTESSA TRIO
Mar 22 Key events next week - healthcare
Mar 17 Weekly CEO Buys Highlight
Mar 14 Have Insiders Been Buying Odonate Therapeutics, Inc. (NASDAQ:ODT) Shares?
Mar 11 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.6 million of Shares
Mar 6 Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
Mar 4 Odonate launches mid-stage study of tesetaxel in breast cancer
Mar 4 Odonate Therapeutics Announces Initiation of CONTESSA 2, a Phase 2 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
See more ODT news...
Indicators
Indicator Value
52 Week High 28.57
52 Week Low 11.54
Average Volume 55,869
200-Day Moving Average 18.2463
50-Day Moving Average 20.137
20-Day Moving Average 23.3885
10-Day Moving Average 24.295
Average True Range 1.4161
ADX 28.61
+DI 18.8717
-DI 24.1996
Chandelier Exit (Long, 3 ATRs ) 21.6417
Chandelier Exit (Short, 3 ATRs ) 24.5383
Upper Bollinger Band 26.6333
Lower Bollinger Band 20.1437
Percent B (%b) 0.19
BandWidth 27.74697
MACD Line 0.8901
MACD Signal Line 1.371
MACD Histogram -0.4809
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.90
Resistance 3 (R3) 25.17 24.29 24.31
Resistance 2 (R2) 24.29 23.40 24.15 24.12
Resistance 1 (R1) 22.84 22.85 22.40 22.57 23.92
Pivot Point 21.96 21.96 21.74 21.82 21.96
Support 1 (S1) 20.51 21.07 20.07 20.24 18.88
Support 2 (S2) 19.63 20.52 19.49 18.68
Support 3 (S3) 18.18 19.63 18.49
Support 4 (S4) 17.91